Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.2K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.2K
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

767
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
767
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

4.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contraceptive use, adherence, and perceptions among women aged 18-45 years in Czechia: a 2019 cross-sectional quota-based online survey.

Reproductive health·2026
Same author

Protection against isoproterenol-induced cardiac injury by sacubitril/valsartan is associated with upregulation of the alternative renin-angiotensin-aldosterone system pathway.

Scientific reports·2026
Same author

Hydrogen sulphide as a potential contributer to cardiovascular protection with sodium-glucose cotransporter 2 inhibition.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Effect of Sacubitril/Valsartan, Ivabradine, and Captopril on Anxiety-like Behavior in Spontaneously Hypertensive Rats.

International journal of molecular sciences·2025
Same author

Melatonin stabilizes atherosclerotic plaques: an association that should be clinically exploited.

Frontiers in medicine·2024
Same author

Considering chronotype to improve hypertension management.

EClinicalMedicine·2024

Related Experiment Video

Updated: Feb 25, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

23.3K

Gene therapy for hypertension.

Ludovit Paulis1,2, Heinrich Franke1, Fedor Simko1,3,4

  • 1a Institute of Pathophysiology, Faculty of Medicine , Comenius University , Bratislava , Slovakia.

Expert Opinion on Biological Therapy
|August 8, 2017
PubMed
Summary

Gene therapy shows promise for reducing blood pressure (BP) and cardiovascular events in rodent models by targeting various molecular pathways. However, clinical application for hypertension requires improved gene delivery and further research in larger mammals.

Keywords:
Gene therapyNO-synthaseRNA interferenceadeno-associated virusadenovirusarterial hypertensionkallikreinnatriuretic peptidesrenin-angiotensin-aldosterone systemvector

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

Related Experiment Videos

Last Updated: Feb 25, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

23.3K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

Area of Science:

  • Cardiovascular Research
  • Gene Therapy
  • Hypertension Management

Background:

  • Current hypertension control and prevention of cardiovascular events remain insufficient.
  • Novel therapeutic strategies for blood pressure reduction are critically needed.
  • Advances in gene therapy offer potential new avenues for treating hypertension.

Purpose of the Study:

  • To review experimental studies on gene therapy for hypertension.
  • To assess the efficacy of gene therapy in reducing blood pressure and related outcomes.
  • To identify challenges and future directions for clinical translation.

Main Methods:

  • Systematic search for studies using gene therapy in hypertension reporting blood pressure outcomes.
  • Analysis of 63 experimental studies in small rodents.
  • Identification of targeted molecular pathways including the renin-angiotensin-aldosterone system, adrenergic receptors, and others.

Main Results:

  • Gene therapy demonstrated feasible targeting of multiple molecular pathways in rodent models.
  • Observed blood pressure reduction ranged from 10-30 mmHg for several months.
  • Some studies reported attenuation of target organ damage and improved survival.

Conclusions:

  • Gene therapy is a promising research tool for hypertension but has not yet reached clinical trials.
  • Enhanced gene transfection efficacy, personalized etiology identification, and larger mammal studies are necessary for clinical application.
  • Gene modulation remains a valuable tool for hypertension research in the interim.